NORTH DALLAS, Texas and PLANO, Texas, April 30 /PRNewswire/ -- The battle for beauty now goes wrinkle-to-wrinkle, as Botox's rival, Dysport(TM), has received FDA clearance and is expected to begin their challenge to Botox(R) sometime within the next sixty days. The arrival of Dysport(TM) into the U.S. aesthetics market is sure to spark heated competition not only between the two wrinkle treatments; but also between medical professionals soon to be promoting one over the other, and as alternate wrinkle reducing options within the same medical spa. Medicis, a U.S. aesthetics giant (known for their popular Restylane(R) and Perlane(R) facial fillers) will promote the Dysport(TM) brand as part of a U.S. sales agreement with the manufacturer, Ipsen. Adding Dysport(TM) to their dermal filler empire positions Medicis as a formidable foe to Allergan and their arsenal of beauty treatments (Botox(R) and the Juvederm(R) hyaluronic acid gel fillers).
Botox(R) by Allergan, with an excellent record of patient safety and reliable results, currently dominates U.S. aesthetics sales, remaining strong even throughout the recent economic downturn. The imminent emergence of their first U.S. rival; however, coupled with news of the FDA's stern ruling that Botox(R) must have stronger product safety warnings might be giving Allergan some cause for concern.
Physician injectors who have worked with both Botox(R) and Dysport(TM) have reported that while the two are relatively comparable, they sometimes prefer one over the other in certain facial areas, due to differences in the onset of results, and spread of effect. Dysport(TM) is decidedly faster-acting and has a greater 'spread' (giving a more 'natural' look); while Botox(R) tends to remain more localized, allowing for greater precision and predictability in the treatment area, but possibly requiring more injections in the course of a treatment.
Jeffrey Adelglass, M.D., F.A.C.S., a c
Copyright©2009 PR Newswire.
All rights reserved